S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
PHASE2CompletedINTERVENTIONAL
Enrollment
50
Participants
Timeline
Start Date
October 31, 2005
Primary Completion Date
January 31, 2007
Conditions
Adenocarcinoma of the Extrahepatic Bile DuctAdenocarcinoma of the GallbladderAdenocarcinoma With Squamous Metaplasia of the GallbladderCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerSquamous Cell Carcinoma of the GallbladderUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer
Interventions
DRUG
sorafenib tosylate
Given orally
OTHER
laboratory biomarker analysis
Correlative studies
Trial Locations (1)
78245
Southwest Oncology Group, San Antonio
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00238212 - S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma | Biotech Hunter | Biotech Hunter